Published in final edited form as:

Bioorg Med Chem Lett. 2015 November 1; 25(21): 4933–4936. doi:10.1016/j.bmcl.2015.04.099.

Syntheses and evaluation of substituted aromatic hydroxamates and hydroxamic acids that target *Mycobacterium tuberculosis*

Mark W. Majewski^a, Sanghyun Cho^b, Patricia A. Miller^a, Scott G. Franzblau^b, and Marvin J. Miller^{a,*}

^aDepartment of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN, 46556, USA

^bInstitute for Tuberculosis Research, College of Pharmacy, MIC 964, Rm. 412, University of Illinois at Chicago, IL, 60612, USA

Abstract

Tuberculosis (TB) continues to remain one of the most threatening diseases in the world. With the emergence of multi-drug resistant (MDR) and extensively drug resistant (XDR) strains, the need to develop new therapies is dire. The syntheses of a focused library of hydroxamates and hydroxamic acids is described, as well as anti-TB activity in the microplate alamar blue assay (MABA). A number of compounds exhibited good activity against *Mtb* with notable compounds exhibiting MIC values in the range of 20–0.71 μ M. This work suggests that both hydroxamates and their free acids may be incorporated into more complex scaffolds and serve as potential leads for the development of anti-TB agents.

Graphical Abstract

Keywords

Tuberculosis; Hydroxamate; Hydroxamic Acid

Tuberculosis (TB), caused by *Mycobacterium tuberculosis* (*Mtb*), is a harsh disease that infects approximately one-third of the global population. TB is a highly contagious disease, the second major cause of death as the result of a bacterial infection worldwide.¹ TB targets the lungs in most cases and can spread quite rapidly, a result of the ease in which this

*phone: 574 631 7571 Fax: 574 631 6652 mmiller1@nd.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Supplementary Material

Data associated with this article, including experimental procedures and characterization data for all compounds, is available with the online version of this article.

infection can be transmitted among individuals. On average, there is a new case of TB each second² and, although most are latent infections, the actual cases of active TB continue to grow, approaching 10 million as of 2010.³ TB exhibits a high mortality rate, with up to 2 million deaths associated with this pathogen every year.⁴ Over the last 25 years, TB has seen a resurgence in both the number of cases and severity of infection.⁵ The emergence of multi-drug resistant (MDR), extensively drug resistant (XDR), and totally drug resistant (TDR) strains has further exacerbated this situation.⁶ TB drug discovery is an arduous process primarily because of the obstacles that need to be circumvented such as the thick, lipophilic cell wall characterized by the presence of mycolic acids and arabinogalactan.⁷ Prior to December 31st 2012, there was a 40 year gap between an FDA approved anti-TB agent, with bedaquiline recently approved.⁸ With this in mind, a current interest in our lab is in the development of new anti-TB agents⁹ based on a scaffold simplification strategy.¹⁰ Herein we report on the syntheses of such compounds and their anti-tubercular activities.

Although there are a number of classic treatments for TB (i.e. isoniazid, rifampin), there remain many issues with them, including drug toxicity, long treatment duration, and adverse drug-drug interactions. In cases where the TB infection is treatable, the regimen consists of administration of multiple drugs for at least six months.¹¹ Fortunately, a number of promising new compounds have been reported that have demonstrated potent activity against TB. Although the majority of these are still in pre-clinical investigations, they may serve as welcome additions in the fight against TB. This list is highlighted by PA-824¹² and BTZ-043¹³ (Figure 1). A common feature to both of these classes of anti-TB agent is the presence of an electron deficient aromatic ring. This moiety continues to be reported as crucial for activity, especially for the BTZ class of compounds.¹⁴

With these findings in mind, we were interested in combining electron deficient systems with more lipophilic hydroxamates and hydroxamic acids and testing them against *Mtb*. Both the hydroxamate and hydroxamic acid functional group have proven to be very important in a multitude of medicinally useful agents.¹⁵ The ability of hydroxamic acids to readily chelate metal ions is well established in the literature,¹⁶ thus making them useful moieties for interactions with metalloproteases. Notably, this family of iron chelators has been incorporated in siderophores and has been found to inhibit lipoxxygenase, matrix metalloproteinases, and histone deacetylases.¹⁷ Beyond just the consideration of metal chelation, we were interested to determine if the combination of the hydroxamate and hydroxamic acid functionalities with aromatic rings of varying electron densities would generate an anti-mycobacterial agent. Generally, the utilization of both hydroxamates and hydroxamic acids in TB therapy is scarce.¹⁸ Here we report on the syntheses of these compounds and evaluation of their anti-TB and anti-microbial activities.

First, simple unsubstituted hydroxamates of interest were generated (Scheme 1). Here, benzoic acid was coupled to both *O*-benzylhydroxylamine hydrochloride and *O*-allylhydroxylamine hydrochloride using *N*-(3-dimethylaminopropyl)-*N'*-ethylcarbodiimide hydrochloride (EDC•HCl) under aqueous conditions to give hydroxamates **2a-b**. To enhance lipophilicity, silylated hydroxamate **2c** was synthesized in 54% yield from **1** and *tert*-butyldimethylsilyl hydroxylamine and EDC•HCl in DCM. Next, hydroxamates with *para*-substituted aromatic rings were generated (Scheme 2). First, the appropriately substituted

benzoic acid, **3**, and substituted hydroxylamine was coupled with EDC•HCl to give hydroxamates **4a-e** in varying yields. Intermediates **4c-e** were then subjected to hydrogenolysis conditions to give hydroxamic acids **5a-c**. Lastly, the *para*-nitrohydroxamic acid **7** was made via the direct reaction of ethyl 4-nitrobenzoate, **6**, with hydroxylamine hydrochloride.

The syntheses of hydroxamates with the 3-nitro-5-(trifluoromethyl) aromatic group are shown in Scheme 3. This is the same moiety that is featured in BTZ-043 and shown to be crucial for activity (Figure 1). Thus, we were curious if combining simple hydroxamates and hydroxamic acids with this key functionality would affect anti-TB activity. EDC coupling of 3-nitro-5-(trifluoromethyl)benzoic acid, **8**, with the appropriate substituted hydroxylamine hydrochloride gave **9a-b** and **10** in varying yields. For the synthesis of **12**, a number of different paths were tested; however, the best involved esterification to give methyl ester **11** followed by treatment with KOH and hydroxylamine hydrochloride (HA•HCl) in MeOH to give **12**. As a result of challenges in the purification of **12**, a crude sample was tested (80-85% pure). We were also interested to see how the absence of the nitro group would affect TB activity, so we coupled 3-bromo-5-(trifluoromethyl)benzoic acid, **13**, to give hydroxamate **14**.

Lastly, Scheme 4 shows the syntheses of hydroxamates from simple malonate monoacids. As an extension of our structure-activity relationship studies, we were interested in further varying substrate polarity and see if malonate based hydroxamates and their corresponding acids demonstrated anti-TB activity. Here Meldrum's acid, **15**, was opened to give malonates **16a-b** which were then coupled to the appropriate substituted hydroxylamine to give hydroxamates **17a-c**. Finally, silyl deprotection with tetrabutylammonium fluoride (TBAF) afforded **18b-c**.

All hydroxamates and hydroxamic acids were then subjected to anti-microbial evaluations. Minimum inhibitory concentration (MIC) data for select compounds against *Mtb* in the microplate alamar blue assay (MABA)¹⁹ are displayed in Table 1. From this data, we observed that some compounds exhibited good media-dependent activity against *Mtb*. Often, differences in MIC values between the two media are attributed to factors such as compound solubility and media age.²⁰ Among the compounds tested, both the hydroxamate protecting group and electronics of the aromatic system did affect activity. The data showed that the benzyl protected hydroxamates had, in general, better activity than the allyl hydroxamates. This is possibly due to the fact that the allyl group represents a decrease in lipophilicity and, as a result, diminished the compound's ability to pass through the thick cell wall of *Mtb*.

Interesting results were also obtained when the electronics of the aromatic ring were varied. When comparing activities among the *para*-substituted hydroxamates and their corresponding acids, we were surprised to see only small changes in anti-TB activity among compounds as both the number and nature of the substituents were varied. Anticipating that activity may be enhanced as the aromatic ring became increasingly electron deficient, we were intrigued by the small and non-linear changes in TB activity among compounds **4c-e** and **5a-c**. Thus, it was especially interesting that the most polar hydroxamate, free acid **7**, demonstrated the best overall anti-TB activity in our library, while other *para*-substituted

hydroxamates, acids, and even benzohydroxamic acid (not shown in Table 1) were substantially less active. Hypothesizing that activity may be further potentiated by making the aromatic ring increasingly electron deficient, we then studied systems featuring 3-nitro-5-(trifluoromethyl) substitution. Here we saw that **9a** was the most active in this series; however, the activity was again inferior to *para*-nitro hydroxamic acid **7**.

With regards to hydroxamate-malonate compounds, compound **17b** was our most potent agent. This hydroxamate, like compounds **4d** and **9a**, exhibited both a very lipophilic group (TBS) and an electron deficient ring (PNB). Anticipating that activity could be further optimized, compounds **17a**, **17c**, and free acid **18** were made and tested. These compounds were inferior in overall activity. Overall, these results helped further solidify the notion that electron deficiency, specifically the incorporation of nitro functionality, may transform simple scaffolds into anti-TB agents. Further, our data illustrated the point that greater lipophilicity may assist in potentiating activity (e.g. **2c**, **4a**, and **9**); however, is not necessarily a requirement for the anti-TB activity of this library.

Representative antibacterial evaluations performed using the Kirby-Bauer agar diffusion assay,²¹ are shown in Table 2. As shown, some compounds that were active against TB were also quite active against *M. vaccae*. Based on the aforementioned anti-TB activity, this result was not completely unexpected since both bacterial strains are from the mycobacteria genus. Additionally, for compounds that showed notable zones of inhibition against *M. vaccae* (**2c**, **7**, **9a**, and **14**) minimum inhibitory concentrations (MICs) were determined. As can be seen **9a** was the most active against *M. vaccae*, with a MIC of 3.13 μ M.

In conclusion, a number of compounds synthesized exhibited notable anti-TB activity (MIC values 15.54 to 0.71 μ M) and specific antimicrobial activity. Although at this stage of our studies the exact target and/or general mode of action remain unknown, these compounds may serve as potential scaffolds for the generation of new anti-TB agents.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We acknowledge Nonka Sevova (Mass Spectrometry and Proteomics Facility, UND) for mass spectroscopic analyses. We acknowledge the University of Notre Dame and the NIH (NIH-2R01-AI054193-05A2) for support of this work. M.W.M acknowledges an ECK Institute Global Fellowship (2014-2015, UND).

References and notes

1. Chitre TS, Bothara KG. J. Chem. Pharm. Res. 2011; 3:479–488.
2. Tuberculosis World Health Organization. 2007. <http://who.int/mediacentre/factsheets/fs104/en/index.html>. Retrieved 12 November 2009. Fact sheet No. 104
3. Dye C, Williams BG. Science. 2010; 328:856–861. [PubMed: 20466923]
4. Kaithamanakallam RP, Karunakaran R, Sri Kumar PS. Int. J. Pharm. Pharm. Sci. 2013; 5:662–664.
5. a) Mays EE. J. Natl. Med. Assoc. 1990; 82:829–831. [PubMed: 2280427] b) Kempker RR, Rabin AS, Nikolaishvili K, Kalandadze I, Gogishvili S, Blumberg HM, Vashakidze S. Clin. Infect. Dis. 2012; 54:e51–e54. [PubMed: 22198790]

6. Velayati AA, Farnia P, Masjedi MR, Ibrahim TA, Tabarsi P, Haroun RZ, Kuan HO, Ghanavi J, Farnia P, Varahram M. *Eur. Respir. J.* 2009; 34:1202–1203. [PubMed: 19880622]
7. Zumla A, Nahid P, Cole ST. *Nat. Rev.* 2013; 12:388–404.
8. Wong EB, Cohen KA, Bishai WR. *Trends Microbiol.* 2013; 21:493–501. [PubMed: 23764389]
9. a) Moraski GC, Oliver AG, Markley LD, Cho S, Franzblau SG, Miller MJ. *Bioorg. Med. Chem. Lett.* 2014; 24:3493–3498. [PubMed: 24909079] b) Cheng Y, Moraski GC, Cramer J, Miller MJ, Schorey JS. *PLoS One.* 2014; 9:e87483/1–e87483/8. [PubMed: 24498115] c) Moraski GC, Markley LD, Cramer J, Hipskind PA, Boshoff H, Bailey MA, Alling T, Ollinger J, Parish T, Miller MJ. *ACS Med. Chem. Lett.* 2013; 4:675–679. [PubMed: 23930153] d) Juarez-Hernandez RE, Franzblau SG, Miller MJ. *Org. Biomol. Chem.* 10:7584–7593. [PubMed: 22895786]
10. Tiwari R, Möllmann U, Cho S, Franzblau SG, Miller PA, Miller MJ. *ACS Med. Chem. Lett.* 2014; 5:587–591. [PubMed: 24900885]
11. Morbidoni H. *Cur. Res. Med. Rev.* 2009; 5:190–200.
12. Singh R, Manjunatha U, Boshoff HIM, Ha YH, Niyomrattanakit P, Ledwidge R, Dowd CS, Lee IY, Kim P, Zhang L, Kang S, Keller TH, Jiricek J, Barry CE III. *Science.* 2008; 322:1392–1395. [PubMed: 19039139]
13. Trefzer C, Skovierova H, Buroni S, Bobovska A, Nenci S, Molteni E, Pojer F, Pasca MR, Makarov V, Cole ST, Riccardi G, Mikusova K, Johnsson K. *J. Am. Chem. Soc.* 2012; 134:912–915. [PubMed: 22188377]
14. Tiwari R, Moraski GC, Krchnak V, Miller PA, Colon-Martinez M, Herrero E, Oliver AG, Miller MJ. *J. Am. Chem. Soc.* 2013; 135:3539–3549. [PubMed: 23402278]
15. a) Flipo M, Beghyn T, Charton J, Leroux VA, Deprez BP, Deprez-Poulain RF. *Bioorg. Med. Chem.* 2007; 15:63–76. [PubMed: 17070058] b) Irwin JJ, Raushel FM, Shoichet BK. *Biochem.* 2005; 44:12316–12328. [PubMed: 16156645] c) Lin YM, Miller MJ. *J. Org. Chem.* 1999; 64:7451–7458.
16. Day JA, Cohen SM. *J. Med. Chem.* 2013; 56:7997–8007. [PubMed: 24074025]
17. Antonello, M. Hydroxamic acids: Biological properties and potential uses as therapeutic agents. In: Rappoport, Z.; Liebman, JF., editors. *The Chemistry of hydroxylamines, oximes, and hydroxamic acids*. Vol. 2. Wiley; New York: 2011. p. 731
18. a) Kohn, H.; Kim, MG.; Krause, KL.; Briggs, JM.; Benedik, M.; Strych, U. Hydroxamate and hydroxylamine compounds inhibiting alanine racemase and having antimycobacterial activity. WO 2005020973 A2. Mar 10. 2005 b) Burgos E, Roos AK, Mowbray SL, Salmon L. *Tetrahedron Lett.* 2005; 46:3691–3694.
19. a) b) De Voss JJ, Rutter K, Schroeder B, Su H, Zhu Y, Barry CE 3rd. *Proc. Natl. Acad. Sci. USA.* 2000; 97:1252–1257. [PubMed: 10655517] c) Cho SH, Warit S, Wan B, Hwang CH, Pauli GF, Franzblau SG. *Antimicrob. Agents Chemother.* 2007; 51:1380–1385. [PubMed: 17210775]
20. Franzblau SG, DeGroote MA, Cho SH, Andries K, Nuermberger E, Orme IM, Mdluli K, Angelobarturen I, Dick T, Dartois V, Lenaerts AJ. *Tuberculosis.* 2012; 92:453–488. [PubMed: 22940006]
21. a) Afonin S, Glaser RW, Berditchevskaja M, Wadhvani P, Gührs K-H, Möllmann U, Perner A, Ulrich AS. *Chem. Bio. Chem.* 2003; 4:1151–1163. b) Murray, PR.; Baron, EJ.; Pfaller, MA.; Tenover, FC.; Tenover, RH. *Manual of Clinical Microbiology*. 7th ed.. American Society for Microbiology; Washington, DC: 1999.

Figure 1.
Two Promising Anti-TB Compounds in Development.

Scheme 1.
Syntheses of Hydroxamates **2a-c**.

Scheme 2.
Syntheses of *para*-Substituted Compounds.

Scheme 3.
Syntheses of 3,5-Substituted Compounds.

Scheme 4.
Syntheses of Hydroxamate Malonates.

Table 1

MIC Determinations (μM) for Select Compounds Against *Mycobacterium Tuberculosis* in the Microplate Alamar Blue Assay

Compound	7H12 ^a	GAS ^b
2a	>100	48.45
2b	>100	>100
2c	>50	24.29
4a	90.42	13.60
4b	>100	37.61
4c	>100	42.26
4d	47.31	15.54
4e	>100	47.31
5a	>100	>100
5b	>100	>100
5c	48.07	>100
7	7.79	0.71
9a	>100	10.65
9b	>100	43.17
10	>100	>100
11	>100	29.96
12 *	19.48	>100
14	>100	80.53
17a	86.59	27.11
17b	>100	3.04
17c	98.65	98.58
18	>100	>100
Rifampin	0.03	<0.016

^a 7H12 = 7H9 medium + casitone, palmitric acid, albumin, and catalase

^b GAS = glycerol-alanine salts medium

* Crude Material Screened

Table 2
Antibacterial Assay Results

Compound	Agar Diffusion Zones (mm)						MIC (μM)	
	<i>B. subtilis</i>	<i>S. aureus</i>	<i>M. luteus</i>	<i>M. vaccae</i>	<i>P. aeruginosa</i>		<i>E. coli</i>	<i>M. vaccae</i>
	ATCC 6633	SG511	ATCC 10240	IMET 10670	K799 /wt	K799/61	DC2	IMET 10670
2c	0	0	0	26/30P	14/18P	0	0	12.5
4d	19* ppt	19 ppt	19P* ppt	15 ppt	14P ppt	14 ppt	0	nt
5b	0	0	0	15.5V	0	18P	16	nt
5c	20	17	0	0	0	14P	0	nt
7	0	0	0	30/33P	13	0	0	6.25
9a	16	20	14/20V	45	0	0	0	3.13
10	20	0	0	14	0	0	17P	nt
14	17.5	20	16	26/32P	0	0	10/15P	12.5
DMSO/MeOH	0	0	0	0	0	0	0	nt
Ciprofloxacin	1.66 μg/mL 19	18	0	20	23	1.66 μg/mL 19/26P	21	nt

KEY:

P: Unclear inhibition zone

*: Misshapen zone of inhibition

nt: Not tested

V: Very unclear inhibition zone

ppt: Compound precipitated in media

* All solutions were prepared by first making a 20 mM solution in DMSO and diluting 10-fold with MeOH to give 2 mM solutions. Plates were incubated at 37 °C for 21 h. *M. vaccae* was incubated 37 °C for 44 h. All zones reported are in mm.